ESMO 2023 | Current state of CDK4/6 inhibitors in metastatic HER2-negative breast cancer

Kevin Kalinsky, MD, MS, Emory University Hospital, Atlanta, GA, discusses the current state of CDK4/6 inhibitors in the treatment of metastatic HR-positive HER2-negative breast cancer, comparing the outcomes of studies that led to the approval of palbociclib, ribociclib and abemaciclib. He discusses trials that are tackling some of the unanswered questions. The Phase II MAINTAIN trial (NCT02632045) demonstrated a significant progression-free survival (PFS) benefit for patients who continued with ribociclib, a CDK4/6 inhibitor, when switching endocrine therapy (ET) at progression. The on-going Phase III postMONARCH (NCT05169567) aims to compare PFS in patients receiving fulvestrant with and without abemaciclib. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.